aPTT

Activated Partial Thromboplastin Time

Coagulación

Última revisión: 7 de abril de 2026. Enfoque de fuentes: contexto estándar de interpretación de laboratorio, material médico de referencia y orientación clínica o de salud pública cuando corresponde.

¿Qué es Activated Partial Thromboplastin Time?

Activated partial thromboplastin time (aPTT) is a coagulation test that measures the time it takes for blood to form a clot through the intrinsic and common coagulation pathways. The test evaluates the function of clotting factors XII, XI, IX, VIII, X, V, II (prothrombin), and I (fibrinogen). In the laboratory, a blood sample is mixed with a phospholipid reagent, a contact activator (such as kaolin, silica, or ellagic acid), and calcium chloride, and the time to clot formation is measured in seconds.

The aPTT is one of the most commonly ordered coagulation tests, used both for screening bleeding disorders and for monitoring anticoagulation therapy. It is particularly sensitive to deficiencies in the intrinsic pathway factors (VIII, IX, XI, XII) and is the standard test for monitoring unfractionated heparin therapy. When used in conjunction with the prothrombin time (PT/INR), which evaluates the extrinsic pathway, the two tests together can help localize which part of the coagulation cascade is abnormal, guiding further diagnostic workup for bleeding or clotting disorders.

Por qué importa

The aPTT is essential for evaluating the body's ability to form blood clots properly. A prolonged aPTT may indicate a bleeding disorder such as hemophilia A (factor VIII deficiency) or hemophilia B (factor IX deficiency), von Willebrand disease, or the presence of an inhibitor like a lupus anticoagulant. In clinical practice, aPTT is critical for monitoring patients on unfractionated heparin therapy to ensure the dose is therapeutic—too little heparin increases clotting risk, while too much increases bleeding risk. The aPTT also serves as a preoperative screening tool to identify unsuspected coagulation abnormalities before surgical procedures.

Rangos de referencia normales

GrupoRangoUnidad
Adults25–35seconds
Therapeutic heparin range60–80seconds
Newborns31–54seconds

Los rangos de referencia pueden variar entre laboratorios. Compara siempre tus resultados con los rangos proporcionados por tu laboratorio.

Qué significan los niveles altos de aPTT

Causas comunes

  • Hemophilia A (factor VIII deficiency) or B (factor IX deficiency)
  • von Willebrand disease
  • Unfractionated heparin therapy
  • Lupus anticoagulant (antiphospholipid syndrome)
  • Disseminated intravascular coagulation (DIC)
  • Liver disease (impaired clotting factor production)
  • Vitamin K deficiency (affects common pathway factors)
  • Factor XI or XII deficiency
  • Specific factor inhibitors (antibodies)

Posibles síntomas

  • Easy bruising
  • Prolonged bleeding from cuts or dental procedures
  • Spontaneous nosebleeds (epistaxis)
  • Heavy menstrual bleeding
  • Joint bleeding (hemarthrosis)—classic in hemophilia
  • Blood in urine or stool
  • Excessive bleeding after surgery or trauma

Qué hacer: A prolonged aPTT requires further investigation with a mixing study—mixing the patient's plasma with normal plasma to determine if the prolongation corrects (suggesting factor deficiency) or persists (suggesting an inhibitor). Based on results, specific factor levels, von Willebrand factor testing, or lupus anticoagulant testing may be ordered. If on heparin, the dose may need adjustment. Severe bleeding may require factor replacement, fresh frozen plasma, or cryoprecipitate.

Qué significan los niveles bajos de aPTT

Causas comunes

  • Extensive cancer (increased procoagulant activity)
  • Acute phase response (increased factor VIII as an acute phase reactant)
  • Early disseminated intravascular coagulation
  • Elevated factor VIII levels
  • Technical or sample issues

Posibles síntomas

  • Usually no direct symptoms from shortened aPTT
  • May be associated with increased thrombotic risk in some contexts

Qué hacer: A shortened aPTT is less commonly clinically significant but may indicate a hypercoagulable state. Evaluate for thrombotic risk factors, particularly if the patient has a history of blood clots. Check factor VIII levels, as elevated factor VIII is both an acute phase reactant and an independent thrombotic risk factor. Clinical correlation is essential.

¿Cuándo se recomienda la prueba de aPTT?

  • As a preoperative coagulation screening test
  • When a bleeding disorder is suspected
  • To monitor unfractionated heparin therapy
  • When evaluating unexplained bruising or prolonged bleeding
  • As part of a DIC workup
  • When lupus anticoagulant or antiphospholipid syndrome is suspected

Preguntas frecuentes

A mixing study is performed when the aPTT is prolonged to distinguish between a clotting factor deficiency and the presence of an inhibitor. The patient's plasma is mixed 1:1 with normal pooled plasma, and the aPTT is repeated. If the aPTT corrects to normal, the patient has a factor deficiency (the normal plasma provides the missing factor). If the aPTT remains prolonged, an inhibitor is present—either a lupus anticoagulant or a specific factor inhibitor (antibody). This distinction is crucial because treatment strategies differ dramatically.
aPTT and PT/INR evaluate different parts of the coagulation cascade. The aPTT tests the intrinsic pathway (factors XII, XI, IX, VIII) and the common pathway (X, V, II, fibrinogen). The PT/INR tests the extrinsic pathway (factor VII and tissue factor) and the common pathway. Used together, they help pinpoint where a coagulation problem lies. A prolonged aPTT with normal PT suggests an intrinsic pathway problem (like hemophilia). A prolonged PT with normal aPTT suggests a factor VII issue. Both prolonged suggests a common pathway or multiple factor problem.
This is one of the most counterintuitive aspects of coagulation medicine. Lupus anticoagulant is an antibody that binds to phospholipids used in the aPTT test, artificially prolonging the clotting time in the test tube—hence the name "anticoagulant." However, in the body, these antibodies promote clotting by activating endothelial cells, platelets, and complement, creating a prothrombotic state. Patients with lupus anticoagulant are at increased risk for venous and arterial thrombosis, not bleeding, despite the paradoxically prolonged aPTT.

Biomarcadores relacionados

Referencias y enfoque de revisión

Las páginas del glosario de biomarcadores son explicaciones educativas y deben interpretarse junto con los rangos de referencia y comentarios proporcionados por tu laboratorio y tu profesional de salud. Para conocer nuestros estándares editoriales y proceso de revisión, consulta nuestra Política editorial y nuestro Proceso de revisión de contenido.

¿Quieres analizar tus niveles de aPTT?

Sube tus resultados de laboratorio para recibir un análisis instantáneo con IA de todos tus biomarcadores.

Subir resultados de laboratorio →

Aviso médico: Esta información es solo educativa y no sustituye el consejo, diagnóstico ni tratamiento médico profesional. Los rangos de referencia pueden variar entre laboratorios. Consulta siempre a tu profesional sanitario para interpretar tus resultados concretos.

Aviso: SymptomGPT no es una herramienta de diagnóstico médico y no ofrece consejo médico. Consulta siempre a un profesional de la salud calificado. Si estás teniendo una emergencia médica, llama de inmediato al número de emergencias de tu zona.